AI Article Synopsis
- The study evaluated the feasibility of deprescribing benzodiazepines (BZDs) and Z drugs that were being misused beyond their prescribed duration, highlighting the need to address undesirable effects.
- Conducted in Bangalore, India, 109 patients were followed for 7 months, with interventions led by pharmacists and psychiatrists, measuring quality of sleep (QoS) and medication costs pre- and post-deprescribing.
- Results indicated that 30.69% of participants successfully reduced or ceased their BZD use, leading to significantly improved QoS and cost savings, suggesting that deprescribing is both viable and beneficial.
Article Abstract
Background: In current clinical practice, regardless of the clinical guidelines, BZDs and Z drugs are used beyond the period of indication, resulting in undesirable effects. This study aimed to assess feasibility of deprescribing amongst patients utilizing BZDs and Z drugs inappropriately for longer duration than the prescribed period. The study also analysed the Quality of Sleep (QoS) and Cost Savings incurred amongst deprescribed patients.
Methods: It was a prospective interventional study conducted in IP and OP settings of Psychiatry Department, Bangalore, India. Based on inclusion criteria, 109 patients were recruited for the study for a period of 7 months. Deprescribing was advised to inappropriate BZD and Z-drug users by clinical pharmacist after discussing with the prescribing psychiatrist. The patients were followed-up twice in a month after deprescribing. QoS was assessed by using Pittsburg Sleep Quality Index (PSQI) scale. The total medications cost incurred per patient/month before and after the intervention among both the groups was measured.
Results: Post-intervention, 40(30.69%) BZD users were deprescribed i.e, either dose tapered 6(5.5%), completely ceased 27(24.8%) or on si opus sit (SOS) BZDs prescription 7(6.4%). A majority of 44(40.36%) patients continued BZDs according to the algorithm. Clonazepam 35(87.5%) was the most deprescribed BZD. Deprescribing of BZDs showed an association with QoS of patients, p-value (<0.05). A statistically significant cost reduction was observed after deprescribing BZDs, (Z = 5.465, p=<0.001).
Discussion: Deprescribing BZDs was associated with decline in its usage; implementing deprescribing practice amongst the inappropriate BZD users is feasible, provides an improved QoS and an economic benefit.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ajp.2019.07.041 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Increased Risk of Sudden Sensorineural Hearing Loss in Patients Receiving Sedative-Hypnotics: A Propensity Score Weighting Cohort Study.
Nat Sci Sleep
December 2024
Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan.
Purpose: Benzodiazepine receptor agonists (BZRAs), including benzodiazepines (BZDs) and Z drugs, are widely prescribed for anxiety and sleep. Therefore, issues of tolerance, dependence and adverse effects are of concern. Recent studies suggested a potential link between BZRAs and hearing problems.
View Article and Find Full Text PDFImpact of 'street' benzodiazepines on drug-related deaths in England, Wales and Northern Ireland.
Drug Alcohol Rev
November 2024
Institute of Pharmaceutical Science, King's College London, London, UK.
Introduction: 'Street' benzodiazepines (BZD) are structurally and pharmacologically related to BZDs licensed for human use. In this study we investigated how street BZDs contribute to overall BZD use and death prevalences in England, Wales and Northern Ireland.
Methods: Data were analysed from deaths reported to the National Programme on Substance Use Mortality with post-mortem BZD detections (1999-2021), BZDs seized from music festivals (2017-2021) and drug samples with BZD detections submitted to Welsh Emerging Drugs and Identification of Novel Substances (WEDINOS) (2017-2021).
Benzodiazepine use and incident risk of sudden cardiac arrest in patients with cardiovascular diseases.
Sci Prog
November 2024
School of Public Health and Emergency Management, School of Medicine, Southern University of Science and Technology, Shenzhen, China.
Background: Benzodiazepines (BZDs) are commonly prescribed as adjunctive drugs for patients with cardiovascular diseases (CVDs), particularly those who experience anxiety or insomnia. However, the relationship between the use of BZDs and incident risk of sudden cardiac arrest (SCA) has not been well investigated. In this study, we aimed to examine the association between the use of BZDs and the incident risk of SCA among patients with CVD.
View Article and Find Full Text PDFFerroptosis involvement in the neurotoxicity of flunitrazepam in zebrafish.
Aquat Toxicol
November 2024
School of Environment and Energy, South China University of Technology, Guangzhou 510006, PR China; The Key Lab of Pollution Control and Ecosystem Restoration in Industry Clusters, Ministry of Education, Guangzhou 510006, PR China; The Key Laboratory of Environmental Protection and Eco-Remediation of Guangdong Regular Higher Education Institutions, Guangzhou 510006, PR China. Electronic address:
In recent years, psychoactive drugs such as benzodiazepines (BZDs) have been frequently detected in water environments, however, there is still limited understanding regarding their potential impact on neurological health and underlying mechanisms. This study evaluated the neurotoxicity of the typical BZD drug flunitrazepam (FLZ, 0.2 and 5 μg/L) in zebrafish embryos and adults, and investigated the relationship between ferroptosis and FLZ-induced neurotoxicity.
View Article and Find Full Text PDFExploring diagnostic biomarkers of type 2 cardio-renal syndrome based on secreted proteins and bioinformatics analysis.
Sci Rep
October 2024
The Affiliated Lihuili Hospital of Ningbo University, Health Science Center, Ningbo University, No.57, Xingning Road, Ningbo, 315040, Zhejiang Province, China.
Article Synopsis
- Chronic heart failure (CHF) can lead to chronic kidney disease (CKD), known as type 2 cardio-renal syndrome (CRS2), but the exact mechanisms and early biomarkers for CKD are not well understood.
- Researchers analyzed several expression datasets to identify key genes linked to CKD and secreted proteins related to CHF, uncovering 225 CKD genes and 316 CHF proteins, with four key gene subgroups involved in CRS2's pathology.
- Machine learning methods highlighted three potential biomarkers (CD48, COL3A1, LOXL1) for CKD, forming a diagnostic model that exhibited strong predictive power and a significant correlation with kidney function metrics.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!